InfuSystem Holdings Appoints Two New Board Members
Mr. Dreyer has served as chief financial officer, chief accounting officerand treasurer of AMN Healthcare Services, Inc. (NYSE: AHS) since September2004. Prior to that, he served as chief financial officer and chiefaccounting officer of Sicor, Inc., a manufacturer of complex pharmaceuticalswith operations in the United States, Italy, Mexico, Lithuania, China andSwitzerland, which was acquired by Teva Pharmaceutical Limited. Prior tojoining Sicor in 1997, Mr. Dreyer served in related senior financial positionswithin the pharmaceutical industry for companies such as Elan Corporation plc,Athena Neurosciences and Syntex. Mr. Dreyer holds a Bachelors Degree fromGolden Gate University in San Francisco and is a certified public accountantin California.
Dr. Freddo has served as chief medical officer of Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS) since July 2006. Prior to joining Anadys Pharmaceuticals,Dr. Freddo served as vice president, clinical site head and development sitehead at Pfizer Global Research and Development, La Jolla. From June 2002until August 2005, Dr. Freddo served as executive director and sitetherapeutic area leader for oncology clinical development in La Jolla. Whileat Pfizer, Dr. Freddo led the team responsible for the registration ofSutent(R) (sunitinib malate), a drug approved by the U.S. Food and DrugAdministration in January 2006 for the treatment of advanced kidney cancer andgastrointestinal stromal tumors. Prior to joining Pfizer, Dr. Freddo held avariety of senior management positions at Wyeth-Ayerst Research from December1996 until June 2002, including senior director, oncology, senior director,infectious diseases, and senior director, transplantation immunology. Dr.Freddo holds a B.S. degree in Medical Technology from the State University ofNew York at Stony Brook and an M.D. degree from the University of NorthCarolina, where he also completed his fellowship training.
Mr. Sean McDevitt, chairman of the board, commented, "We are pleased towelcome David and James as the newest members of our board of directors, bothof whom share our vision and commitment to improving the lives of cancerpatients and helping to build InfuSystem into a world-class provider ofambulatory infusion pumps and associated clinical services for oncologypractices and their patients. David has the ideal combination of bothfinancial and healthcare experience, which will make him a valuable additionto our audit committee. James brings extensive medical and clinicalexperience, which will be an important resource as we accelerate our outreachactivities within the healthcare community."
About InfuSystem Holdings, Inc.
InfuSystem is the leading provider of ambulatory infusion pumps andassociated clinical services for oncology practices and their patients in theU.S. These pumps allow for the gradual delivery of a drug over a period ofdays in the privacy of one's home, compared to bolus infusion chemotherapytreatments that are given in a single high dose over a short period of time.Improved efficacy of the drugs, patient comfort, reimbursement to doctors forappropriate services and continuity of care all play a role in the growingtrend toward this form of treatment. InfuSystem's pumps are primarily usedfor colorectal cancer, but they have been approved for other forms of cancer,thereby greatly enhancing the market opportunity for InfuSystem.
Except for the historical information contained herein, the mattersdiscussed in this press release are forward-looking statements that involverisks
You May Also Like